Table I. Clinical features of the 18 CLL samples subjected to iTRAQ-MS.
| Clinical feature | M-CLL (n = 9) | UM-CLL (n = 9) | p |
|---|---|---|---|
| Age at diagnosis (median), years | 67 | 70 | 0.694 |
| Gender (males/females) | 3/6 | 6/3 | 0.347 |
| Prior therapy (treated/untreated)a | 3/6 | 2/7 | 0.620 |
| Leukocyte count at time of sampling (median), ×109/liter | 78.4 | 135.8 | 0.423 |
| High-risk chromosomal abnormalities (17p− and/or 11q−; yes/no)b | 2/7 | 2/7 | 1.000 |
| IGHV (median), %c | 7.48 | 0.34 | 0.00004 |
The statistical significance of the difference (p values) between the two groups was determined using a two-tailed Mann-Whitney U test for parametric data and Fisher's exact test for nonparametric data, respectively.
a Prior therapy consisted of various combinations of glucocorticoid, chlorambucil, fludarabine, or fludarabine plus cyclophosphamide.
b CLL samples were tested by interphase fluorescence in situ hybridization for del17p13 (17p−), del11q23 (11q−), trisomy 12 (12+), and del13q14 (13q−). 17p and 11q− are regarded as high-risk chromosomal abnormalities.
c IGHV refers to somatic mutation in the IGHV gene of CLL cells compared with the gene sequence of the nearest germ line, where <2% was classed as UM-CLL and ≥2% was classed as M-CLL.